Government ❯ Health ❯ Healthcare

Pharmaceuticals

Drug Regulation Drug Safety Drug Pricing Medication Supply Advertising Prescription Medications Drug Approval Prescription Drugs Drug Advertising Risk Management Regulatory Affairs Drug Approval Process Drug Manufacturing Drug Procurement FDA Drug Testing Oncology Medications 340B Program International Trade Regulatory Agencies Quality Control Supply Chain Issues Clinical Trials Manufacturing in Mexico Pharmaceutical Advertising Regulatory Oversight Medication Pricing Contract Compliance Adverse Effects Public Health Vaccine Production Insulin Medicine Supply Drug Quality Cannabis Naming Medicines Fees and Payments Application Process Rejection Process Marketing Authorization Generic Medicines Supply Chain Management Regulation Drug Administration Generic Drugs Drug Development Advisory Committees Debt Management Children's Medicine Mifepristone Pharmacy Regulations Drug Review Process Procurement Processes Medical Representatives Illegal Products Hospital Pharmacy Medication Delivery Home Delivery Services Supplier Compliance Regulatory Programs Export Targets

Hemmati Emerges as Front-Runner to Lead FDA’s Vaccine and Biologics Center

HHS and the White House say the choice remains under review.

FDA Escalates Crackdown on Drug Ads, Moves to Close ‘Adequate Provision’ Loophole

FDA Sends Mass Warnings, Seeks to End 1997 Drug Ad Rule After White House Directive

FDA Launches PreCheck to Accelerate Domestic Drug Plants

HHS Opens Applications for 340B Rebate Model Pilot

FDA Publishes Over 200 Complete Response Letters for 2020–24 Drug Applications